JNJ-95475939
Phase 2Small molecule
Johnson & JohnsonJNJ-95475939 is one of 31 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.
2
Indications
1
Total Trials
0
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Nereus
VVanda Pharmaceuticals
Phase 3
Elidel
BayerPhase 3
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
OPA-15406
OtsukaPhase 3
Product 0405
FFougera Pharmaceuticals Inc.
Phase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
Stapokibatrt
KKeymed Biosciences Co.Ltd
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-95475939. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company